Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI

Market Cap	63.66B 56.56B 52.79B 48.12B 90.75B 6,120B 91.59B 639B 248B 3,128B 239B 234B 10,040B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 71.94B 67.14B 61.2B 115B 7,783B 116B 813B 315B 3,979B 304B 297B 12,770B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-02	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-08	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
04-01	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-13	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
01/07/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Actavis Inc Stock NYSE

Stocks

US9426831031

Pharmaceuticals

Valuation: Actavis Inc

Latest news: Actavis Inc

Press Releases: Actavis Inc

News in other languages: Actavis Inc

Managers and Directors: Actavis Inc

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	01/12/2016
Robert Michael PSD	President	55	08/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	08/05/2020
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.61%	-3.43%	+39.40%	+112.31%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+37.67%	+65.02%	617B
ABBVIE INC.	+1.11%	-0.58%	+11.10%	+77.28%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.21%	+40.71%	356B
ROCHE HOLDING AG	-0.95%	-4.05%	+21.60%	+39.37%	333B
NOVARTIS AG	-1.46%	-2.89%	+11.84%	+24.60%	267B
ASTRAZENECA PLC	-1.35%	-5.43%	-4.69%	+8.40%	244B
AMGEN INC.	-1.04%	-2.79%	+35.52%	+51.34%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+30.92%	+95.33%	179B
Average	-0.23%	-3.39%	+27.17%	+57.15%	410.8B
Weighted average by Cap.	+0.42%	-3.33%	+30.52%	+68.96%

	2018	2019
Net sales	15.79B 14.03B 13.09B 11.93B 22.51B 1,518B 22.71B 158B 61.39B 776B 59.27B 57.99B 2,490B	16.09B 14.29B 13.34B 12.16B 22.94B 1,547B 23.15B 161B 62.57B 791B 60.41B 59.09B 2,538B
Net income	-5.1B -4.53B -4.23B -3.85B -7.27B -490B -7.33B -51.15B -19.82B -250B -19.13B -18.72B -804B	-5.27B -4.68B -4.37B -3.98B -7.51B -507B -7.58B -52.9B -20.5B -259B -19.79B -19.36B -831B
Net Debt	21.89B 19.45B 18.15B 16.55B 31.21B 2,104B 31.5B 220B 85.13B 1,076B 82.19B 80.4B 3,453B	17.3B 15.38B 14.35B 13.08B 24.67B 1,664B 24.9B 174B 67.29B 850B 64.97B 63.56B 2,729B

End-of-day quote NYSE
- ^USD	-